Zealand Pharma enters US partnership over pump system

Biotech company Zealand Pharma has gained access to an infusion pump from the US-based Deka, which will be used with the drug dasiglucagon for the treatment of severe low blood sugar. Zealand Pharma is also granted worldwide exclusive rights for the pump in combination with the drug.
Photo: Stine Bidstrup/ERH
Photo: Stine Bidstrup/ERH
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

Zealand Pharma and Deka Research & Development have partnered up to developed an infusion pump system, which will include the drug dasiglucagon, meant to treat patients with congenital hyperinsulinism (CHI), which is severe and persistent low blood sugar, Zealand Pharma reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading